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ABSTRACT
Our immune system is engaged in a continuous battle against invading pathogens, many of which
have evolved to survive in intracellular niches of mammalian hosts. A variety of cellular processes
are involved in preventing bacterial invasion or in killing bacteria that successfully invade host cells.
Recently, the Rab GTPase Rab32 emerged as critical regulator of a host defense pathway that can
eliminate bacterial pathogens. Salmonella enterica is an intracellular bacterium and a major cause of
infections and deaths in humans. Rab32 and its guanine nucleotide exchange factor BLOC-3 are
essential to prevent the growth of the human-restricted Salmonella enterica serovar Typhi (S. Typhi)
in mice, a non-susceptible host. The importance of the Rab32/BLOC-3 pathway has been recently
conﬁrmed by the ﬁnding that broad-host Salmonella enterica serovars deliver 2 bacterial effectors to
neutralize this pathway and infect mice. Rab32 has also been shown to control infection by Listeria
monocytogenes, another medically relevant intracellular pathogen. In addition, genetic evidence
indicate a possible role of Rab32 in controlling leprosy, a disease caused by Mycobacterium leprae in
humans, suggesting that a Rab32-dependent pathway can also act as a host defense pathway in
humans. The Rab32 role in bacterial pathogen restriction is discussed here and compared to the










Many cellular processes are involved in preventing bacte-
rial pathogens from replicating within mammalian hosts
(reviewed in refs. 1, 2). Phagocytic cells (i.e., macro-
phages and dendritic cells) are the cells of the immune
system devoted to internalizing and destroying bacterial
invaders. Phagocytic processes are well studied, as well
as many of the processes that lead to the activation of
antimicrobial mechanisms and bacterial removal.3 Reac-
tive oxygen species, nitric oxide, antimicrobial peptides
and toxic concentrations of heavy metals are part of the
molecular arsenal used by phagocytic cells to kill bacte-
rial pathogens.4-8 However, successful bacterial patho-
gens evolved to neutralize this antimicrobial attack and
survive within phagocytic cells. Investigating the bacte-
rial molecules involved in this host-pathogen battle has
recently led to the discovery of a novel host defense path-
way, where a central role is played by the Rab GTPase
Rab32. This pathway protects some mammalian species,
e.g. mice, from the attack of the human-adapted patho-
gen Salmonella enterica serovar Typhi (S. Typhi).9,10
However, it does not protect mice from broad-host Sal-
monella enterica (Salmonella) serovars, as these serovars
have evolved potent bacterial effectors to neutralize this
pathway.10 The Rab32-dependent pathway might be a
broad host-defense pathway against intracellular patho-
gens. In fact, genetic evidence suggests a role for Rab32
in preventing Mycobacterium leprae infections.11,12 In
addition, Rab32 and its close homolog Rab38 have also
been reported to control Listeria monocytogenes.13 In
this mini-review we discuss the ﬁndings that led to the
identiﬁcation of the Rab32 host defense pathway in the
context of Salmonella infections, evidence of its involve-
ment in controlling other intracellular pathogens and the
role of Rab32 in other cellular trafﬁcking processes.
Salmonella: Establishing different diseases
in different hosts
Salmonella is a facultative intracellular pathogen that is
well adapted to live in mammalian hosts. There are more
than 2 thousand serovars belonging to this species and
they constitute a main cause of infectious diseases. S.
Typhi and the less common Salmonella enterica serovar
Paratyphi A (S. Paratyphi) are responsible for more than
26 million cases of typhoid fever, a life-threatening dis-
ease that kills hundreds of thousands of people each
year, mainly in the developing world.14-16 In contrast, all
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the other Salmonella serovars cause in humans a milder
and local infection, i.e. a gastroenteritis known as salmo-
nellosis. Remarkably, while S. Typhi and S. Paratyphi are
host-restricted serovars that can only infect humans, the
majority of Salmonella serovars can infect a broad-range
of animal hosts and cause, in many of these hosts, a sys-
temic disease that is often fatal.17 For example, the well-
known Salmonella serovar Typhimurium is responsible
for common outbreaks of gastroenteritis in humans but
can infect systemically cattle, sheep and mice, with the
last being a common laboratory model of Salmonella sys-
temic infection.
Salmonella colonizes the host by initially invading the
epithelial cells lining the intestinal tract. This invasion is
an active process induced by Salmonella via the delivery
of effectors through a specialized secretion system, called
type III secretion system.18 These effectors act coordi-
nately to induce macropinocytosis and the formation of
a compartment known as the Salmonella-containing vac-
uole, where this pathogen thrives and multiplies. Some of
the type III secretion effectors also participate in induc-
ing an inﬂammatory response that confers Salmonella an
advantage over commensal intestinal bacteria.19 Once
Salmonella has multiplied in the intestinal epithelial cells,
the bacterium can get access to the underlying connec-
tive tissue or lamina propria.20 The lamina propria is
rich in macrophages and other immune cells that medi-
ate the initial immune response to pathogens. In this tis-
sue an important battle is played at the level of the
macrophages and possibly other phagocytic cells.21
These cells can eliminate bacteria, including many
pathogens. However, if the bacteria succeed in overcom-
ing host-cell defenses that act to restrict bacterial growth,
the host will not be able to mount an immune response
to the bacteria and the infection will spread systemically.
Bacteria will survive and multiply in phagocytic cells,
with the result that the same cells that should have
restricted the infection actually become a vehicle to
spread the infection to the bloodstream and peripheral
organs. Depending on the speciﬁc host and the speciﬁc
Salmonella serovar involved, either the bacterium will be
efﬁciently killed in the intestinal lamina propria or a sys-
temic infection will develop. The function of a second
type III secretion system is required for a Salmonella
broad-host serovar, S. Typhimurium, to establish a sys-
temic infection in the mouse.22 This second type III
secretion system is only expressed once the bacteria have
established their intracellular niche, and is required for
the bacteria to survive and replicate in macrophages.23
However, the exact mechanisms through which the effec-
tors delivered by this system favor bacterial survival and
the establishment of a systemic infection are only
recently starting to emerge.
Salmonella Typhi host-restriction: Critical role of a
Rab32/BLOC-3-dependent trafﬁcking pathway
S. Typhi can only infect humans.16 Although it is respon-
sible for a life-threatening disease that has been affecting
humans for centuries, the molecular mechanisms at the
basis of its human-adaptation and the ability to spread
systemically are still mostly unknown. For many years,
the entry and trafﬁcking of the broad-host serovar S.
Typhimurium within infected cells, particularly epithelial
cells, have been investigated in detail. S. Typhimurium is
ﬁrst internalized in an EEA1 positive compartment,
which then acquires Rab7 and endolysosomal markers,
such as the glycoprotein LAMP-1.24,25 This compart-
ment is highly dynamic, exchanges material with the
endolysosomal system and engages cytoskeleton ele-
ments (reviewed in refs. 26-28). Only recently a main
difference in the intracellular biology of S. Typhi and S.
Typhimurium has been reported. S. Typhi recruits the
GTPases Rab32, Rab38 and Rab29 (also known as
Rab7L1) to its vacuole, but S. Typhimurium does not.9,29
These 3 proteins constitute a subfamily of Rab GTPases
distinct from the primordial endocytic and exocytic Rab
subfamilies.10,30 Both in epithelial cells and macrophages
the majority of S. Typhi-containing vacuoles are deco-
rated by Rab32, Rab38 and Rab29, while these Rab
GTPases are never recruited to the S. Typhimurium-con-
taining vacuole.9,29 What is the molecular basis for this
striking difference? Why does the S. Typhimurium vacu-
ole not acquire Rab32, Rab38 and Rab29? The reason
resides in 2 bacterial effectors that target these GTPases.
They are both expressed and delivered by S. Typhimu-
rium, but not S. Typhi. The ﬁrst to be identiﬁed was
GtgE, a bacteriophage protein previously shown to be
required for S. Typhimurium virulence in mice.29,31
GtgE is a cysteine protease that speciﬁcally cleaves these
3 related Rab GTPases.9,29,32 The second S. Typhimu-
rium effector targeting Rab32 is SopD2, a protein that
acts as a GTPase activating protein (GAP) for Rab32 and
induces its dissociation from the vacuolar membrane.10
Bacterial effectors and toxins have very often worked
as excellent tools to clarify fundamental processes in cell
biology. One of the most paradigmatic examples is the
Listeria monocytogenes effector ActA that has greatly
contributed to the discovery of the molecular basis of
actin nucleation.33 Likewise, the S. Typhimurium effector
GtgE played a critical role in the identiﬁcation of a novel
cell biology process, i.e., a trafﬁcking pathway controlling
bacterial growth. GtgE was initially described as a bacte-
rial effector preventing Rab29 localization onto the S.
Typhimurium-containing vacuole. It was then shown to
be a cysteine protease highly speciﬁc for Rab29, Rab32
and Rab38.9,29 Based on the observation that GtgE is
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conserved in the majority of broad-host Salmonella sero-
vars and absent from S. Typhi and S. Paratyphi, the
hypothesis was made that it confers Salmonella serovars
the ability to infect a broad-range of hosts. This hypothe-
sis was initially tested in primary murine macrophages,
which are able to clear the human-restricted S. Typhi
and prevent S. Typhi from infecting mice. When GtgE
was introduced in the S. Typhi genome, macrophages
were no longer able to kill S. Typhi.9 In addition, mice
inoculated with a strain of S. Typhi expressing GtgE
were systemically infected with this strain. This ability of
GtgE to enhance S. Typhi survival in mouse macro-
phages and infectivity in mice was shown to be the result
of its protease activity toward Rab32. In fact, murine
macrophages depleted of Rab32 were found to be unable
to clear S. Typhi. Rab38 and Rab29 are also substrates of
GtgE, but siRNA-mediated depletion of these 2 Rabs has
no effect on the ability of macrophages to kill S. Typhi.9
Rab38 is highly related to Rab32 and has been shown to
work redundantly with Rab32 in other cellular processes.
However, as Rab38 expression is limited to speciﬁc tis-
sues,34 it is probably not expressed in primary murine
macrophages.
Over the past decade Rab32 and Rab38 have emerged
as critical molecules in the biogenesis of lysosomal
related organelles (LROs), as discussed below. The Bio-
genesis of Lysosome-related Organelle Complexes
(BLOC) 1, 2, and 3 are also fundamental players in the
biogenesis and maturation of these organelles.35,36 In
addition to Rab32, one of these complexes, BLOC-3, was
shown to be required for S. Typhi killing in primary
murine macrophages. Interestingly, at the same time
BLOC-3 was reported to be the guanine nucleotide
exchange factor for Rab32 and Rab38.37 All these obser-
vations indicated the existence of a Rab32 regulated traf-
ﬁcking event controlling the killing of S. Typhi in
primary murine macrophages. Noteworthy, mice defec-
tive for BLOC-3 were also found to be more susceptible
to S. Typhi infection.10 Indeed, while wild-type mice
completely clear S. Typhi infection, S. Typhi can be
recovered from tissues of BLOC-3-deﬁcient mice 2
months after the initial inoculation. These results indi-
cate that the Rab32/BLOC-3 trafﬁcking pathway is cen-
tral for S. Typhi-host restriction.
The Rab32/BLOC-3 trafﬁcking pathway is
neutralized by broad-host Salmonella serovars
Does the Rab32/BLOC-3 trafﬁcking pathway only
restrict S. Typhi infections? Interestingly, both BLOC-3-
deﬁcient mice and Rab32-deﬁcient mice are signiﬁcantly
more susceptible to the broad-host Salmonella serovar S.
Typhimurium.10 Surprisingly, removing GtgE from S.
Typhimurium does not signiﬁcantly impair the ability of
S. Typhimurium to infect mice and does not restore
Rab32 on the Salmonella-containing vacuole, suggesting
that S. Typhimurium also inhibits the recruitment of
Rab32 to the bacterial vacuole through a different effec-
tor.10 This S. Typhimurium effector was identiﬁed as
SopD2, an effector that is not expressed by S. Typhi due
to the fact that it is present as a pseudogene in the S.
Typhi genome. SopD2 is a GTPase activating protein
(GAP) that inactivates Rab32.10 As such, it prevents
Rab32-dependent trafﬁcking in S. Typhimurium-
infected cells and confers this broad-host Salmonella
serovar the ability to infect mice (Fig. 1). Remarkably,
Figure 1. Rab32/BLOC-3 dependent antimicrobial pathway and the mechanisms used by S. Typhimurium to neutralize it. After entry
into a host cell, Salmonella resides in a compartment known as the Salmonella-containing vacuole. In contrast to S. Typhi (right panel),
S. Typhimurium (left panel) delivers to the host 2 effector proteins, GtgE and SopD2. Both effectors block the Rab32/BLOC-3-dependent
antimicrobial pathway by targeting Rab32. This pathway is envisioned to deliver an antimicrobial factor (small red circles) to the S.
Typhi-containing vacuole. GtgE is a protease that cleaves Rab32, whereas SopD2 acts as a GTPase activating protein for Rab32 and pro-
motes its dissociation from the vacuole. In addition, SopD2 interacts with Rab7 and inhibits its activity, which is required for the delivery
of endosomal contents to lysosomes. EE, early endosome; LE, late endosome; Lys, lysosome.
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deletions of both GtgE and SopD2 from the S. Typhimu-
rium genome render S. Typhimurium unable to infect
mice.10 SopD2 has also been recently shown to inhibit
another trafﬁcking process, the delivery of endocytic
cargo to lysosomes. SopD2 acts as an inhibitor of the
GDP-GTP exchange on Rab7 through direct binding of
Rab7.38 The N-terminus of SopD2 is sufﬁcient for Rab7
binding and inhibition of Rab7 function,38 while a C-ter-
minal arginine (R315) is required for the SopD2 GAP
activity on Rab32.10 These observations indicate that
SopD2 has 2 different functions that can be assigned to
different components of its structure.
Either the protease GtgE or the GAP SopD2 are able
to prevent most of the Rab32 delivery to the vacuole and
confer S. Typhimurium most of the ability to infect
mice.10 Therefore, these effectors act in effect redun-
dantly to block Rab32 trafﬁcking and facilitate the estab-
lishment of a systemic infection in the mouse.
Interestingly, a S. Typhimurium mutant defective for
GtgE and SopD2, although unable to infect wild-type
mice, can establish a systemic infection in mice deﬁcient
for the Rab32/BLOC-3-dependent pathway, indicating
that GtgE and SopD2 are completely dispensable in the
absence of this antimicrobial pathway.10 These recent
results conﬁrmed a central role for the Rab32/BLOC-3
trafﬁcking pathway in host defense.
Rab32 and related GTPases in controlling other
intracellular bacterial pathogens
Is the Rab32/BLOC-3-dependent host-defense pathway
also able to restrict other intracellular pathogens? The
genus Mycobacterium contains a number of species that
cause serious diseases in humans, such as tuberculosis
and leprosy. After internalization into host macrophages
Mycobacteria reside in a compartment (phagosome)
where they establish a suitable niche for survival.3,39
Mycobacterium leprae (M. leprae) is a human-adapted
pathogen that causes a chronic infectious disease called
leprosy.40,41 Most individuals exposed to M. leprae do
not develop the disease, which may be explained, at least
in part, by innate resistance provided by an individual’s
genetic background. Several studies have demonstrated a
link between host genetic factors and susceptibility to
leprosy (for reviews see refs. 42, 43). Genome-wide asso-
ciation studies of leprosy have been critical to identify
loci associated with susceptibility to M. leprae.11,12,44
Most of the identiﬁed risk loci encode factors involved in
immune responses against infections. Remarkably, a
polymorphism in the Rab GTPase Rab32 was also associ-
ated with increased susceptibility to M. leprae.11,12 There
is a signiﬁcant lack of knowledge on how eukaryotic cells
deal with M. leprae infections at a molecular level. The
challenge of cultivating M. leprae outside its host
together with the limited availability of suitable animal
models for the study of leprosy have limited research on
the mechanisms at the basis of this disease. However, the
emerging importance of Rab32 trafﬁcking pathway in
the cell defense response against bacterial pathogens
strongly suggests that this Rab protein may play similar
roles in controlling M. leprae infections (Fig. 2).
In contrast to M. leprae, the interaction of the related
pathogen Mycobacterium tuberculosis (M. tuberculosis)
with the host has been investigated at cellular level and
several Rab GTPases have been implicated in the interac-
tion. At an early stage, the M. tuberculosis phagosome
Figure 2. Rab32 in the control of intracellular bacterial pathogens. (A) After internalization into host macrophages, Rab32 is recruited to
the Salmonella-containing vacuole (SCV). Rab32 and BLOC-3 are required for S. Typhi killing in mouse macrophages, which possibly
occurs through the delivery of an antimicrobial cargo (red circles) to the bacterial vacuole.9 (B) After internalization in dendritic cells, L.
monocytogenes initially resides in an early phagosome. To avoid phagolysosome formation and therefore bacterial killing, L. monocyto-
genes lyses the vacuole (Listeria-containing vacuole; LCV) and escapes to the cytosol where it replicates. After escaping to the cytosol, L.
monocytogenes is captured in a membranous compartment, a multi-layered structure decorated by a complex containing Rab32 and its
interactors PHB and PHB-2.13 (C) M. leprae replicates within macrophages.71 Although a polymorphism in Rab32 has been associated to
increased susceptibility to leprosy,11,44 the exact role that Rab32 may play in controlling M. leprae infection is not known. GC, Golgi Com-
plex; ER, Endoplasmic Reticulum.
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lacks antimicrobial properties. The capacity to kill patho-
gens is acquired during a process of phagosome matura-
tion, which includes phagosome acidiﬁcation and
acquisition of oxidative and hydrolytic enzymes.3 This
process requires the interaction of the phagosome with
components of the endocytic pathway, including Rab5
and Rab7.39 While Rab5 associates with early phago-
somes, Rab7 characterizes late phagosomes and pro-
motes their fusion with lysosomes. M. tuberculosis
controls the recruitment of different Rab GTPases to the
phagosome during the time of infection maintaining a
niche with features of an early endocytic compartment.45
In addition to Rab5, the M. tuberculosis phagosome also
recruits Rab14 and Rab22a, both contributing to the
maintenance of phagosomes in an early stage of matura-
tion.46-48 On the contrary, the recruitment of Rab
GTPases related with latter steps of phagosomal matura-
tion is prevented. Indeed, Rab7 and Rab20, which are
involved in phagosome acidiﬁcation,45 as well as Rab10,
which is involved in early stages of maturation,49 are not
observed on the M. tuberculosis phagosome. Therefore, a
series of Rab GTPases regulated events avoid phagosome
maturation and maintain an appropriate niche for M.
tuberculosis survival. A possible role of the Rab32/
BLOC-3 pathway in the control of M. tuberculosis sur-
vival is still unknown.
Listeria monocytogenes (L. monocytogenes) is an intra-
cellular pathogen that causes listeriosis, one of the most
lethal foodborne infections, with 20 to 30% of clinical
infections resulting in death.50 The bacterium is internal-
ized into phagocytic cells and non-phagocytic host cell
through receptor-mediated recognition of speciﬁc bacte-
rial proteins.51 Once internalized, L. monocytogenes
actively escapes from the bacterial vacuole into the cyto-
sol and then is transmitted to neighboring cells through
actin-based movements induced by ActA-driven actin
polymerization. L. monocytogenes killing in dendritic
cells has been recently shown to be dependent on Rab32
and Rab38.13 The authors showed that the Rab32-posi-
tive compartment containing L. monocytogenes in den-
dritic cells is surrounded by a multilayered membrane.
They also reported that Rab32 is recruited to the surface
of bacteria that have escaped to the cytosol, suggesting
that this Rab32-positive compartment containing L.
monocytogenes is a compartment sequestering bacteria
from the cytosol after their initial attempt of escape from
the vacuole (Fig. 2).13 However, they also showed that
the Rab32-dependent control of L. monocytogenes
growth is not mediated by autophagic mechanisms.13
Further investigations will be required to understand the
exact mechanism of Rab32-mediated pathogen killing.
Valuable hints could derive from the analysis of Rab32
trafﬁcking function in non-phagocytic cells.
Rab32 subfamily of GTPases as regulators of
membrane trafﬁcking to lysosome-related
organelles (LROs)
Rab32 and its closely related isoform Rab38 have both
been described as regulators of membrane trafﬁcking to
lysosome-related organelles (LROs). Rab38 expression is
mostly conﬁned to pigment cells. Rab32 is highly
expressed in a variety of tissues including the liver, heart,
spleen and testis,52,53 suggesting it performs a key role in
these tissues. Expression levels are high in cells contain-
ing LROs.29,30 LROs are cell-type speciﬁc vesicles that
share many similarities with lysosomes, yet perform a
diverse range of functions. These include melano-
somes,54 platelet granules,55 lytic granules,56 the MHC
class II compartment and lamellar bodies.57 The observa-
tion that S. Typhi and L. monocytogenes recruit Rab32 to
their vacuoles suggests that the S. Typhi- and the Liste-
ria-containing vacuoles are also LROs. Many LROs have
a critical function in immune defenses.58,59 Some of
them, such as the lytic granules of T cells or the neutro-
phils granules, have a secretory function and they have
also been called “secretory lysosomes.” Lytic granules
contain molecules, such as perforin and granzymes, that,
when released extracellularly, mediate target cell death.59
The neutrophils granules are ﬁlled with a variety of
hydrolytic enzymes and antimicrobial peptides that are
able to kill bacteria once secreted into the extracellular
environment.60 Given the similarities between LROs and
lysosomes and the fact that these 2 organelles exist
within the same cell in many cell types, there must be
mechanisms to distinguish between them and ensure the
correct membrane proteins and luminal contents are
appropriately trafﬁcked to their target organelle.
Some genetic conditions result in deﬁciencies of
LROs.61 Hermansky-Pudlack syndrome (HPS) is a
genetic disorder that results in hypopigmentation, pro-
longed bleeding and pulmonary ﬁbrosis, caused by
defects in the biogenesis of melanosomes, platelets and
lung ﬁbroblast lamellar bodies, respectively.62,63 HPS is
associated with mutations in BLOC-1, BLOC-2, BLOC-3
and AP-3. Rodent models of HPS display pigmentation
defects (Swank et al., 1998). Interestingly, chocolate mice,
which have a mutation in Rab38, display a mild pigmen-
tation phenotype.64 This is in stark contrast to the severe
hypopigmentation found when melanocytes from choco-
late mice were depleted of Rab32 by siRNA treatment.65
Recently, the contribution of these Rabs in melanosome
biogenesis has been explored in greater detail. Rab32 and
Rab38 function within a trafﬁcking pathway that trans-
ports melanin-producing enzymes to maturing melano-
somes and interacts with components of ubiquitous
trafﬁcking machineries, such as BLOC-2, AP-1 and
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AP-3.34,63,66 Membrane-bound Rab32 and Rab38 were
shown to physically interact with these proteins and this
interaction was enhanced between the active GTP-bound
forms of the Rabs and BLOC-2 and AP-3. This is consis-
tent with an interaction between these proteins and the
active membrane bound forms of Rab32 and Rab38.66
Platelets are anucleated blood cells that play an essen-
tial role in homeostasis and host defense against patho-
gens. Platelets contain 2 types of LROs, a-granules
(AGs) and dense granules (DGs), which are released at
the site of vascular injury.67 It has been shown that DGs
originate from late endocytic organelles (possible MVBs)
in a model cell line and that the sorting signals that are
required to send cargo to DGs are recognized by AP-3.68
These cells also contain conventional lysosomes suggest-
ing mechanisms must exist to target molecules to AGs
and DGs and away from other endocytic organelles.
Both Rab32 and Rab38 colocalise with AP-3 and are
enriched on immature DGs. Moreover, both Rab32 and
Rab38 colocalise with Rab7, but not Rab5, reinforcing
the hypothesis that DGs have a late endocytic origin.
Both Rab32 and Rab38 are involved in the transport of
cargo-containing vesicles to DGs but their exact role in
vesicle tethering or fusion has not been separated. How-
ever, siRNA depletion of either Rab32 or Rab38 cannot
be fully compensated by the remaining Rab GTPase sug-
gesting they may fulﬁl separate functions in platelet
granule maturation.68
Rab32 appears to be a multifunctional protein,
depending upon its cellular localization and the cell type.
Rab32 has been shown to function as an A-kinase
anchoring protein (AKAP) at both mitochondria and
LROs.69,70 AKAPs act to retain other signaling enzymes
at speciﬁc intracellular locations in order to coordinate
protein phosphorylation events and direct them toward
their substrates. Rab32 and Rab38 have been demon-
strated to function within trafﬁcking pathways for the
delivery of proteins to both dense granules and melano-
somes, in platelets and melanocytes, respectively. These
specialized trafﬁcking pathways employ unique trafﬁck-
ing machineries, including AP-3, BLOC-1, BLOC-2 and
BLOC- 3. This pathway is distinct from that of conven-
tional lysosome biogenesis. As such, it would not be sur-
prising to ﬁnd that Rab32 (and Rab38) had a role in the
biogenesis of other LROs, such as the lamellar bodies of
lung type II epithelial cells. However, this remains to be
seen.
Conclusions
Rab32 and its closely related homolog Rab38 control the
delivery of specialized cargo to LROs. They are also
recruited to the vacuoles containing bacterial pathogens,
such as S. Typhi and L. monocytogenes, and they are
essential to protect mammalian hosts, e.g., mice, from
these pathogens. Rab32 and its GEF BLOC-3 are funda-
mental to restrict S. Typhi in mouse and are components
of a powerful host defense pathway. A bacterial pathogen
that can successfully infect mice, such as S. Typhimu-
rium, has evolved 2 bacterial effectors to target and neu-
tralize this pathway. The exact mechanism underlying
the Rab32/BLOC-3-dependent clearance of bacterial
pathogens is still unknown. However, based on the fact
that Rab32 and the related Rab38 control the delivery of
specialized cargo to LROs in melanocytes and platelets, it
is very likely that this pathway delivers a cargo with anti-
microbial properties to the S. Typhi- and the L. monocy-
togenes-containing vacuole. Future work clarifying the
nature of this cargo will have a tremendous impact in the
understanding of innate immune mechanisms protecting
against bacterial pathogens.
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